# DEC 2 2 2008

# 510(k) Summary f Safety andffectiven

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, Address, and Contact

Lin-Zhi International, Inc. 687 North Pastoria Avenue Sunnyvale, CA 94085 Phone: (408) 732-3856 Fax: (408) 732-3849 Email: mtlin@lin-zhi.com

Contact: Marie Lin, Ph.D. President, R&D Director

# Device Name and Classification

Classification Name:

Enzyme immunoassay, Opiates Class II, DJG (91 Toxicology), 21 CFR 862.3650

Norbuprenorphine calibrators, Class II DLJ (91 Toxicology), 21 CFR 862.3200

Norbuprenorphine controls, Class I, LAS (91 Toxicology), 21 CFR 862.3280

Common Name: Proprietary Name:

Homogeneous Buprenorphine Enzyme Immunoassay LZI Buprenorphine Enzyme Immunoassay, Calibrators and Controls: for Beckman Coulter® Synchron Systems

# Legally Marketed Predicate Device(s)

The LZI Buprenorphine Enzyme Immunoassay (EIA) is substantially equivalent to the CEDIA® Buprenorphine Assay (K040316) manufactured by Microgenics Corporation. LZI's Buprenorphine Enzyme Immunoassay is identical or similar to its predicate in terms of intended use, method principle, device components, and clinical performance.

# Device Description

The LZI Buprenorphine assay is a homogeneous enzyme immunoassay with ready-to-use liquid reagent. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, buprenorphine-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when free drug is present in the sample, antibody would bind to free drug, the unbound buprenorphine-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at $3 4 0 ~ \mathrm { { n m } }$

# Intended Use

The Lin-Zhi International (LZl) Buprenorphine Enzyme Immunoassay, when used in conjunction with Beckman Coulter $\wp$ Synchron $\mathrm { L X } @ $ , $\mathrm { C X } @ $ , and UniCel $^ \mathrm { \textregistered }$ DxC automated clinical system analyzers, is intended for the qualitative and semi-quantitativc determination of norbuprenorphine (buprenorphine metabolite) in human urine, at a cutoff value of $1 0 ~ \mathrm { { n g / m L } }$

The Norbuprenorphine Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the Lin-Zhi International (LZl) Buprenorphine Enzyme Immunoassay with Beckman Coulter Synchron $\mathbf { L X } @$ $\mathrm { C X @ }$ and UniCel $^ \mathrm { \textregistered }$ DxC automated clinical system analyzers.

The Norbuprenorphine Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter Synchron $\mathrm { L X } @ $ $\mathrm { C X } { \mathfrak { B } }$ and UniCel $^ \mathrm { \textregistered }$ DxC automatcd clinical system analyzers.

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method (1,2). Clinical consideration and professional judgement should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

# Comparison to Predicate Device

The LZI Buprenorphine Enzyme Immunoassay is substantially equivalent to the CEDIA® Buprenorphine Assay (by Microgenics Corporation), cleared by the FDA under the premarket notification K0403 16 for its stated intended use.

The following table compares LZI's Buprenorphine Enzyme Immunoassay with the predicate device, CEDIA® Buprenorphine Assay by Microgenics Corporation.

<table><tr><td rowspan=1 colspan=1>DeviceCharacteristics</td><td rowspan=1 colspan=1>Subject DeviceLZI Buprenorphine EnzymeImmunoassayfor Beckman Coulter® Synchron Systems</td><td rowspan=1 colspan=1>Predicate DeviceCEDIA® Buprenorphine Assay(K040316)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Lin-Zhi International (LZI)Buprenorphine Enzyme Immunoassay,when used in conjunction with BeckmanCoulter Synchron LX®, CX®, andUniCel® DxC automated clinical systemanalyzers, is intended for the qualitativeand semi-quantitative detcrmination ofnorbuprenorphine (buprenorphinemetabolite) in human urine, at a cutoffvalue of 10 ng/mL.This assuy provides a rapid screening procedurefor determining the presence of norbuprenorphine(buprenorphine metabolite) in urine. The assayprovides only a preliminary analytical result. Amore specific alternative chemical method must beused in order to obtain a confirmed unalyticalresult. Chromatography/mass spectrometry(GC/MS or LC/MS) is the preferred confirmatorymethod (1,2). Clinical consideration andprofessional judgement should be exercised withany drug of abuse test result, particularly when thepreliminary test result is positive.</td><td rowspan=1 colspan=1>The CEDIA Buprenorphine assay is ahomogeneous enzyme immunoassay forqualitative or semi-quantitativedetermination of the presence ofbuprenorphine in human urine at cutoffconcentration of 5 ng/mL. The assayprovides a simple and rapid analyticalscreening procedure to detectbuprenorphine in human urine.The assay provides only a preliminary analyticalresult. A more specific ulternative chemiculmethod must be used to obtuin a confirmedanalytical result. Gas chromatogruphy/massspectrometry (GC/MS) is the preferredconfirmatory method. Clinical and professionaljudgement should be applied to uny drug of abusetest result, particularly when preliminary resultsare used.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Norbuprenorphine (buprenorphinemetabolite)</td><td rowspan=1 colspan=1>Buprenorphine</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>10 ng/ml</td><td rowspan=1 colspan=1>5 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Urine</td></tr><tr><td rowspan=1 colspan=1>CalibratorsLevel</td><td rowspan=1 colspan=1>6 Levels(0, 5, 10, 20, 40, 100 ng/mL)</td><td rowspan=1 colspan=1>5 Levels(0, 5, 20, 50 and 75 ng/ml)</td></tr><tr><td rowspan=1 colspan=1>Controls Level</td><td rowspan=1 colspan=1>2 Levels(7 ng/mL, 13 ng/mL)</td><td rowspan=1 colspan=1>2 Levels(3 ng/mL, 7 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8°C until expiration date</td><td rowspan=1 colspan=1>2-8°C until expiration date</td></tr></table>

Performance Characteristics Summary: Precision: Semi-Quantitative, $\mathbf { n g / m L }$ CX4CE Analyzer:   

<table><tr><td rowspan=1 colspan=1>Drug:Norbuprenorphine</td><td rowspan=1 colspan=1>Sampleconcentration,ng/mL</td><td rowspan=1 colspan=1>Mean,ng/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean,ng/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run(n=21)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run-to-Run(n=20 over 2weeks)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>n/a</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>14.9</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>6.3</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>15.1</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.9</td></tr></table>

LX20 Pro Analyzer:   

<table><tr><td rowspan=1 colspan=1>Drug:Norbuprenorphine</td><td rowspan=1 colspan=1>Sampleconcentration,ng/mL</td><td rowspan=1 colspan=1>Mean,ng/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean,ng/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run(n=21)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run-to-Run(n=-20 over 2weeks)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>O </td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>n/a</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>242.2</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>22.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>13.1</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>9.3</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>7.3</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>15.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>18.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.6</td></tr></table>

DxC600 Analyzer:   

<table><tr><td rowspan=1 colspan=1>Drug:Norbuprenorphinc</td><td rowspan=1 colspan=1>Sampleconcentration,ng/mL</td><td rowspan=1 colspan=1>Mean,ng/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean,ng/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run(n=21)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run-to-Run(n=20 over 2weeks)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>162.1</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>16.4</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>17.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.0</td></tr></table>

# Precision: Qualitative, mA/min

CX4CE Analyzer:   

<table><tr><td rowspan=1 colspan=1>Drug:Norbuprenorphine</td><td rowspan=1 colspan=1>Sampleconcentration,ng/mL</td><td rowspan=1 colspan=1>Mean,mA/min</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean,mA/min</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run(n=21)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run-to-Run(n=20 over 2weeks)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>367.4</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>366.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>379.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>378.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>389.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>390.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>398.8</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>400.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>411.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>412.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>424.6</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>425.3</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>437.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>438.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>448.6</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>451.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>463.6</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>465.4</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.5</td></tr></table>

LX20 Pro Analyzer:   

<table><tr><td rowspan=1 colspan=1>Drug:Norbuprenorphine</td><td rowspan=1 colspan=1>Sampleconcentration,ng/mL</td><td rowspan=1 colspan=1>Mean,mA/min</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean,mA/min</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run(n=21)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run-to-Run(n=20 over 2weeks)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>368.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>371.7</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>385.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>386.2</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>398.0</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>401.6</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>417.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>414.9</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>437.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>433.7</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>452.7</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>450.2</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>469.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>465.0</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>490.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>482.9</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>503.3</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>498.5</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.8</td></tr></table>

DxC600 Analyzer:   

<table><tr><td rowspan=1 colspan=1>Drug:Norbuprenorphine</td><td rowspan=1 colspan=1>Sampleconcentration,ng/mL</td><td rowspan=1 colspan=1>Mean,mA/min</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean,mA/min</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run(n=21)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Run-to-Run(n=20 over 2weeks)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>378.7</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>384.9</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>395.1</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>397.6</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>6.3</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>414.6</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>415.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>428.4</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>428.5</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>449.1</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>446.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>467.5</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>463.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>484.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>481.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>503.3</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>499.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>518.7</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>515.6</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.3</td></tr></table>

# Precision: Qualitative, Positive/Negative

<table><tr><td rowspan=1 colspan=2>CX4CE Analyzer</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Run to Run</td></tr><tr><td rowspan=1 colspan=1>Sample[ ], ng/mL</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>- 100%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>- 75%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>- 50%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>- 25%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>13 POS/8 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>12 POS/8 NEG</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>+ 50%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>+ 175%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>+ 200%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr></table>

<table><tr><td rowspan=1 colspan=2>LX20 Pro Analyzer</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Run to Run</td></tr><tr><td rowspan=1 colspan=1>Sample[ ], ng/mL</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>- 100%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>- 75%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>- 50%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>+ 25%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>+ 50%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>+ 175%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>+ 200%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr></table>

<table><tr><td rowspan=1 colspan=2>DxC600 Analyzer</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Run to Run</td></tr><tr><td rowspan=1 colspan=1>Sample[ ], ng/mL</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>#ofDetermination</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>- 100%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>- 75%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>- 50%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>- 25%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 NEG</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>18 POS/3 NEG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>13 POS/7 NEG</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>+ 175%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr><tr><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>+ 200%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21 POS</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20 POS</td></tr></table>

# Detection Limit:

The lowest concentration that can be differentiated from the negative urine with $9 5 \%$ confidence is determined as $3 ~ \mathrm { { n g / m L } }$ on all three platforms of instruments.

# Linearity:

CX4CE Instrument: $3 { \cdot } 9 0 ~ \mathrm { \mathfrak { n } g / \mathrm { { m L } } }$ LX20 Pro Instrument: $3 { \mathrm { - } } 7 0 ~ { \mathrm { \textmu } } { \mathrm { g / m L } }$ DxC Instrument: $\mathrm { 3 { - } 7 0 \ n g / m L }$

# Method comparison against GC/MS confirmation device:

CX4CE Instrument: 83 clinical unaltered samples, $9 3 . 0 \%$ agrecment with positive, $9 7 . 5 \%$ agreement with negative samples)

LX20 Pro Instrument: 82 clinical unaltered samples, $9 7 . 4 \%$ agreement with positive, $9 5 . 3 \%$ agreement with negative samples)

DxC Instrument: 83 clinical unaltered samples, $9 7 . 4 \%$ agreement with positive, $9 5 . 3 \%$ agreement with negative samples)

# Specificity and Endogenous Substances:

No significant undesired cross reactants or endogenous substance interference werc observed. See product insert for list of compounds tested.

# Summary:

The information provided in this pre-market notification demonstrates that the LZI Buprenorphine Enzyme Immunoassay is substantially equivalent to the legally marketed predicated device for its general intended use. Substantial equivalence was demonstrated through comparison of intended use and physical properties to the commercially available predicate device as confirmed by gas chromatography/mass spectrometry, an independent analytical method. The information supplied in this pre-market notification provides reasonable assurance that the LZI Buprenorphine Enzyme Immunoassay is safe and effective for its stated intended use.

Lin-Zhi International, Inc. c/o Marie Lin   
President   
687 North Pastoria Ave Sunnyvale, CA 94085

# DEC 22 2008

Re: k081008 Trade/Device Name: Buprenorphine Enzymc Immunoassay and Norbuprenorphine Calibrators and Controls

Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate test system Regulatory Class: Class II Product Code: DJG, DLJ and LAS Dated: November 05, 2008 Received: November 07, 2008

Dear Ms. Lin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S. DV.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Premarket Notification

# Indications for Use Statement

510(k) Number (if known): k081008

Device Name: Buprenorphine Enzyme Immunoassay and Calibrators and Controls. for Beckman Coulter® Synchron Systems

# Indications For Use:

The Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay, whcn used in conjunction with Beckman Coulter $\wp$ Synchron $\mathrm { L X } @$ , $\mathrm { C X } @$ , and UniCel $\textsuperscript { \textregistered }$ DxC automated clinical systcm analyzers, is intended for the qualitative and semi-quantitative determination of norbuprenorphine (buprenorphine metabolite) in human urinc, at a cutoff value of $1 0 \mathrm { n g / m L }$ .

The Norbuprenorphine Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter $\textsuperscript { \textregistered }$ Synchron $\mathrm { { \small L X } } \mathfrak { P }$ $\mathrm { C X } { \mathfrak { B } }$ and UniCel $^ \mathrm { \textregistered }$ DxC automated clinical system analyzers.

The Norbuprenorphine Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay with Beckman Coulter $\wp$ Synchron $\operatorname { L X @ , C X @ } _ { \operatorname { \sharp } }$ and UniCel $\textsuperscript { \textregistered }$ DxC automated clinical system analyzers.

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method). Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive

Prescription Use  AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)